Skip to main content
SpringerLink
Log in

Hodentumoren

  • Conference paper
Maligne Lymphome, Hodentumoren, Bronchuskarzinom, Ovarialkarzinom

Part of the book series: Angewandte Onkologie ((AONKOLOGIE))

  • 19 Accesses

Zusammenfassung

Hodentumoren stellen die häufigste maligne Erkrankung bei jungen Männern zwischen dem 15. und 35. Lebensjahr dar. Die österreichische Krebsstatistik weist für das Jahr 1984 insgesamt 101 Hodentumoren in dieser Altersgruppe aus [1], das heißt, daß bei jedem 3. jungen Mann mit einer malignen Erkrankung ein Hodentumor diagnostiziert wird (Tabelle 1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Krebskrankenstatistik 1984 (1986) Statistische Nachrichten 41: 172

    Google Scholar 

  2. Henderson BE, Ross RK, Pike MC, et al (1983) Epidemiology of testis cancer. In: Skinner DG (ed) Urological cancer. Crune and Stratton, New York, p 237

    Google Scholar 

  3. Waterhouse J, Muir C, Shanmugaratnam K, et al (eds) (1982) Cancer incidence in five continents, vol IV. International Agency for Research on Cancer, Lyon

    Google Scholar 

  4. Waterhouse J, Muir C, Correa P, et al (eds) (1976) Cancer incidence in five continents, vol VIII. International Agency for Research on Cancer, Lyon

    Google Scholar 

  5. Schottenfeld D, Warshauer ME (1982) Testis. In: Schottenfeld D, Fraumeni JS (eds) Cancer epidemiology and prevention. Saunders, Philadelphia, p 947

    Google Scholar 

  6. Depue RH (1984) Maternal and gestational factors affecting the risk of cryptorchidism and inguinal hernia. Int J Epidemiol 13: 311

    Article  PubMed  CAS  Google Scholar 

  7. Lin RS, Kessler I (1979) Epidemiologic findings in testicular cancer. Am J Epidemiol 110: 357

    Google Scholar 

  8. Loughlin JE, Robboy SJ, Morrison AS (1980) Risk factors for cancer of the testis. N Engl J Med 303: 112

    Article  PubMed  CAS  Google Scholar 

  9. Milham S (1976) Neoplasia in the wood and pulp industry. Ann NY Acad Sci 271: 294

    Article  PubMed  Google Scholar 

  10. Rhomberg W, Schmoll HJ (1978) High incidence of metal workers among patients with testicular cancer. In: Niebergs HE (ed) Prevention and detection of cancer, part I: prevention. Etiology prevention methods, volt. Marcel Dekker, New York, p 1737

    Google Scholar 

  11. Mills PK, Newell GR, Johnson DE (1984) Testicular cancer associated with employment in agriculture and oil and natural gas extraction. Lancet i: 207

    Google Scholar 

  12. Coldman AJ, Elwood JM, Gallagher RP (1982) Sports activities and risk of testicular cancer. Br J Cancer 46: 749

    Article  PubMed  CAS  Google Scholar 

  13. Jones WG, Appleyard I (1985) Delay in diagnosing testicular tumours. Br Med J 290: 1550

    Article  CAS  Google Scholar 

  14. Forsberg L, Olsson AM (1983) Examination of the pathological scrotum with dynamic and static ultrasound. Br J Radio! 56: 921

    Article  CAS  Google Scholar 

  15. Appleyard I (1986) Presentation of testicular tumours. In: Jones WG, Milford Ward A, Anderson CK (eds) Germ cell tumours II. Advances in the biosciences, vol 55. Pergamon Press, Oxford New York Toronto Sydney Frankfurt/M. p 295

    Google Scholar 

  16. Mostofi FK (1973) Testicular tumours: epidemiologic, etiologic and pathologic features. Cancer 32: 1186

    Article  PubMed  CAS  Google Scholar 

  17. Friedman NB, Moore RA (1946) Tumours of the testis: a report on 922 cases. Military Surgeon 99: 573

    PubMed  CAS  Google Scholar 

  18. Dixon FJ, Moore RA (1952) Tumours of the male sex organs, fasc 31 b and 32. In: Atlas of tumour pathology. Armed Forces Institute of Pathology, Washington

    Google Scholar 

  19. Mostofi FK, Price EB (1973) Tumours of the male genital system, fasc 8. In: Atlas of tumour pathology (second series). Armed Forces Institute of Pathology, Washington

    Google Scholar 

  20. Mostofi FK, Sobin LH (1977) International histological typing of testes tumours, No 16. WHO, Geneva

    Google Scholar 

  21. Collins DH, Pugh RCB (1964) The pathology of testicular tumours. Livingstone, Edinburgh

    Google Scholar 

  22. Pugh RCB (1976) Combined tumours. In: Pugh RCB (ed) Pathology of the testis. Blackwell, Oxford, p 245

    Google Scholar 

  23. Kuzmits R, Schernthaner G, Krisch K (1987) Serum neuronspecific enolase: a marker for response to therapy in seminoma. Cancer 60: 1017

    Article  PubMed  CAS  Google Scholar 

  24. Kuzmits R, Aiginger P, Schwarz HP, et al (1983) HCG and Alpha-1-Fetoprotein bei Hodentumoren. Aktuelles aus Diagnostik and Therapie 81: 45

    Google Scholar 

  25. Kühböck J, Aiginger P, Kuzmits R, et al (1987) Prognostic value of tumour marker determinations in testicular cancer patients. Cancer Detect Prey 10: 389

    Google Scholar 

  26. Peckham MJ (1981) Investigation and staging: general aspects and staging classification. In: Peckham MJ (ed) The management of testicular tumours. Edward Arnold, London, p 89

    Google Scholar 

  27. Pschyrembel W (1982) Klinisches Wörterbuch, 254. Aufl. de Gruyter, Berlin New York, S 1232

    Google Scholar 

  28. Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: results of a multicentre study. Report from the Medical Research Council Working Party on Testicular Tumours (1985). Lancet is 8

    Google Scholar 

  29. Seeber S, Higi M, Niederle N, et al (1981) Individualisierte Intervallverkürzung bei der chemotherapeutischen Induktionsbehandlung solider Tumoren. Deutsch Med Wochenschr 106: 1741

    Article  CAS  Google Scholar 

  30. Tapia FJ, Polak JM, Barbosa AJA, et al (1981) Neuron-specific enolase is produced by neuroendocrine tumours. Lancet is 808

    Google Scholar 

  31. Cooper EH, Splinter TAW, Brown DA, et al (1985) Evaluation of a radioimmunoassay for neuron-specific enolase in small cell lung cancer. Br J Cancer 52: 333

    Article  PubMed  CAS  Google Scholar 

  32. Aiginger P (1983) Prognostische Faktoren. In: Aiginger P (Hrsg) Neue Aspekte in der Klinik and Fortschritte in der Chemotherapie der malignen Hodentumoren. Facultas, Wien, S 49

    Google Scholar 

  33. Thomas GM, Rider WD, Dembo At et al (1982) Seminoma of the testis: results of treatment and patterns of failure after radiation therapy. Int J Rad Oncol Biol Phys 8: 165

    Article  CAS  Google Scholar 

  34. Thomas GM, Herman JG (1984) The role of radiation in the management of seminoma. In: Kurth KA (ed) Progress and controversies in the oncological urology. Liss, New York, p 91

    Google Scholar 

  35. Thomas GM (1985) Controversies in the management of testicular seminoma. Cancer 55: 2296

    Article  PubMed  CAS  Google Scholar 

  36. Mirimanoff RO, Shipley U, Dosoretz DE, et al (1985) Pure seminoma of the testis: the results of radiation therapy in patients with elevated human chorionic gonadotropin titers. J Urol 134: 1124

    PubMed  CAS  Google Scholar 

  37. Swartz DA, Johnson DE, Hussey DH (1984) Should an elevated human chorionic gonadotropin titer alter therapy for seminoma? J Urol 131: 63

    PubMed  CAS  Google Scholar 

  38. Herman JG, Sturgeon J, Thomas GM (1983) Mediastinal prophylactic irradiation in seminoma. Proc ASCO 2: 133 (abstract #C-521)

    Google Scholar 

  39. Ball D, Barrett A, Peckham J (1982) The management of metastatic seminoma testis. Cancer 50: 2289

    Article  PubMed  CAS  Google Scholar 

  40. van Oosteram AT, Williams SD, Cortes-Funes H, et al (1984) Treatment of semino-mas with chemotherapy. In: Kurth KA (ed) Progress and controversies in the ontological urology. Liss, New York, p 103

    Google Scholar 

  41. Doornbos JF, Hussey DH, Johnson DE (1975) Radiotherapy for pure seminoma of the testis. Radiology 116: 401

    PubMed  CAS  Google Scholar 

  42. Williams SD, Einhorn L (1985) Treatment of seminoma. In: Marc Garnick (ed) Contemporary issues in clinical oncology. Churchill, Livingstone, p 37

    Google Scholar 

  43. Samuels M (1974) Bleomycin in the therapy of testis tumors. In: Soper WT, Gott AB (eds) New drug seminar on bleomycin. NCI, Bethesda, p 124

    Google Scholar 

  44. Einhorn LH, Donohue J (1977) Cis-diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87: 293

    PubMed  CAS  Google Scholar 

  45. Brown JH, Kennedy B) (1965) Mithramycin in the treatment of disseminated testicular neoplasms. N Engl J Med 272: 111

    Google Scholar 

  46. Einhorn LH, Williams SD, Troner M, et al (1981) The role of maintenance therapy in disseminated testicular cancer. N Engl J Med 305: 727

    Article  PubMed  CAS  Google Scholar 

  47. Fitzharris BM, Kaye SB, Saverymuttu S (1980) VP16–213 as a single agent in advanced testicular tumors. Eur J Cancer 16: 1193

    Article  PubMed  CAS  Google Scholar 

  48. Williams SD, Einhorn LH, Greco FA, et al (1980) VP16–213 salvage therapy for refractory germinal neoplasm. Cancer 46: 2154

    Article  PubMed  CAS  Google Scholar 

  49. Aiginger P, Kühböck J, Kuzmits R, et al (1982) VP-16 therapy in cis-platinum resistant testicular tumours. In: Periti P, Grassi GG (eds) Proc 12th Int Congr Chemotherapy Washington, p 1426

    Google Scholar 

  50. Aiginger P, Kühböck J, Kuzmits R, et al (1983) Salvage therapy in testicular tumour patients resistant to vinblastine-bleomycin-cisplatinum. In: Spitzy KH, Karrer K (eds) Proc 13th Int Congr Chemotherapy, Vienna. Egermann, Wien, p 241/20

    Google Scholar 

  51. Williams S, Stablein D, Muggia F, et at (1987) Early stage testis cancer: the testicular cancer intergroup studies. Proc 5th Int Conf Adj Ther Cancer, Tucson, 42 (abstract #30)

    Google Scholar 

  52. Weissbach L. Abschließende Daten der Bonner Therapiestudie, Stadium I. Im Druck.

    Google Scholar 

  53. Hoskin P, Dilly S, Easton D, et al (1986) Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. J Clin Oncol 4: 1031

    PubMed  CAS  Google Scholar 

  54. Vugrin D, Chen A, Feigl P (1987) Long-term survival rates in the patients with stage I germ cell tumors of the testis (GCTT). Proc 5th Int Conf Adj Ther Cancer, Tucson, 43 (abstract # 31 B)

    Google Scholar 

  55. Carter SK (1979) A perspective on adjuvant chemotherapy of testicular cancer. J Cancer Res Clin Oncol 95: 1

    Article  PubMed  CAS  Google Scholar 

  56. Maier JG, Van Buskirk K (1970) Treatment of testicular germ cell malignancies. JAMA 213: 97

    Article  PubMed  CAS  Google Scholar 

  57. Williams C (1977) Current dilemmas in the management of non-seminomatous germ cell tumors of the testis. Cancer Treat Rev 4: 275

    Article  PubMed  CAS  Google Scholar 

  58. Pizzocaro G, DePalo G, Milani A, et al (1977) Adjuvant chemotherapy related to prognostic subgroups in stage Il testicular carcinoma. Proc ASCO 18 (abstract # C-471)

    Google Scholar 

  59. Hartlapp JH, Weissbach L, Bussar-Maatz R (1987) Adjuvant chemotherapy in nonseminomatous testicular tumour stage II. Int J Androl 10: 277

    Article  PubMed  CAS  Google Scholar 

  60. Vugrin D, Chen A, Feigl P (1987) Long-term survival rates in stage II germ cell tumors of the testis (GCTT). Proc 5th Int Conf Adj Ther Cancer, Tucson, 42 (abstract # 31 A)

    Google Scholar 

  61. Dewar JM, Spagnolo DV, Jamrozik KD, et al (1987) Predicting relapse in stage I nonseminomatous germ cell tumours of the testis. Lancet is 454

    Google Scholar 

  62. Williams SD, Birch R, Einhorn LH, et al (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 316: 1435

    Article  PubMed  CAS  Google Scholar 

  63. Javadpour N (1978) Biologic tumor markers in the management of testicular and bladder cancer. Urology 12: 177

    Article  PubMed  CAS  Google Scholar 

  64. Tesoro-Tess JD, Pizzocaro G, Zanoni F, et al (1985) Lymphangiography and computerized tomography in testicular carcinoma: how accurate in early stage disease? J Urol 133: 967

    PubMed  CAS  Google Scholar 

  65. Einhorn LH, Williams SD, Mandelbaum I, et al (1981) Surgical resection in disseminated testicular cancer following chemotherapeutic reduction. Cancer 48: 904

    Article  PubMed  CAS  Google Scholar 

  66. Aiginger P, Schwarz HP, Kuzmits R, et al (1983) HLA-A, B, C and DR antigens and testicular cancer: a prospective study. Proc AACR 24: 190

    Google Scholar 

  67. Aiginger P (1983) HLA-Antigene und maligne Hodentumoren. In: Aiginger P (Hrsg) Neue Aspekte in der Klinik und Fortschritte in der Chemotherapie der malignen Hodentumoren. Facultas, Wien, S 31

    Google Scholar 

  68. Aiginger P (1983) Chemotherapie bei Patienten mit malignen Hodentumoren; eigene Ergebnisse. In: Aiginger P (Hrsg) Neue Aspekte in der Klinik und Fortschritte in der Chemotherapie der malignen Hodentumoren. Facultas, Wien, S 41

    Google Scholar 

  69. Samuels ML, Lanzotti VJ, Holoye PY, et al (1976) Combination chemotherapy in germinal cell tumours. Cancer Treat Rev 3: 185

    Article  PubMed  CAS  Google Scholar 

  70. Einhorn LH, Williams SD (1980) Chemotherapy of disseminated testicular cancer — a random prospective study. Cancer 46: 1339

    Article  PubMed  CAS  Google Scholar 

  71. Vugrin D, Herr HW, Whitmore WF, et al (1981) VAB-6 combination chemotherapy in disseminated cancer of the testis. Ann Intern Med 95: 59

    PubMed  CAS  Google Scholar 

  72. Peckham MJ, Barrett A, Liew KH, et al (1983) The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin ( BEP ). Br J Cancer 47: 613

    Google Scholar 

  73. Steurer G, Kuzmits R, Pavelka M, et al (1985) Vinblastine induced thrombocytopenia during polychemotherapy of disseminated testicular cancer. Blut 51: 172

    Google Scholar 

  74. Williams S, Einhorn L, Greco A, et al (1985) Disseminated germ cell tumors: a comparison of cisplatin plus bleomycin plus either vinblastine (PVB) or VP-16 (BEP). Proc ASCO 4: 100 (abstract # C-390)

    Google Scholar 

  75. Samson MK, Fischer RL, Stephens RL, et al (1981) Vinblastine, bleomycin and cisdiamminedichloroplatinum in disseminated testicular cancer: response to treatment and prognostic correlations — a SWOG study. Eur J Cancer 16: 1359

    Google Scholar 

  76. Scheulen ME, Niederle N, Höffken K, et al (1985) Ifosfamide/MESNA (IF/ M) alone or in combination with etoposide (IF/M+E): salvage therapy for patients with metastasized nonseminomatous testicular cancer (NSTC). Proc ASCO 4: 97 (abstract # C-379)

    Google Scholar 

  77. Trump DL, Hortvet L (1985) Etoposide and very high dose cisplatin: salvage therapy for patients with advanced germ cell neoplasms. Cancer Treat Rep 69: 259

    PubMed  CAS  Google Scholar 

  78. Wheeler BM, Loehrer PJ, Williams SD, et al (1986) Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4: 28

    PubMed  CAS  Google Scholar 

  79. De Vita)r VT (1983) The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer. Cancer 51: 1209

    Google Scholar 

  80. Goldie JH, Coldman AJ, Gudauskas GA (1982) Rationale for the use of alternating noncross-resistant chemotherapy. Cancer Treat Rep 66: 439

    PubMed  CAS  Google Scholar 

  81. Aiginger P, Schwarz HP, Kuzmits R, et al (1982) Ifosfamide and cisplatinum in testicular tumour patients resistant to vinblastine-bleomycin-cisplatinum. Proc 13th Int Cancer Congr, Seattle, PPS-28: 180 (abstract #1014)

    Google Scholar 

  82. Kuzmits R, Ludwig H, Aiginger P (1988) Ergebnisse mit dem Standard BVP-Therapieprotokoll und mit sequentiell alternierender BVP-EIP Therapie bei Patienten mit ausgedehnt metastasierten Hodentumoren („Bulky disease“). Tumor Diagnostik & Therapie 9: 33

    Google Scholar 

  83. Donohue JP, Einhorn LH, Williams SD (1980) Cytoreductive surgery for metastatic testis cancer: considerations of timing and extent. J Urol 123: 876

    PubMed  CAS  Google Scholar 

  84. Tiffany P, Morse MJ, Bosl G, et al (1986) Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage Ill germ cell tumors. Cancer 57: 978

    Article  PubMed  CAS  Google Scholar 

  85. Kühböck J, Kuzmits R, Ludwig H, et al (1986) Resection of residual tumour after chemotherapy in testicular cancer: observation and late relapse. Blut 53: 132

    Google Scholar 

  86. Kuzmits R, Ludwig H (1986) Late relapse in testicular cancer from a residual tumour. Lancet i: 1207

    Google Scholar 

  87. Vugrin D, Whitmore WF (1984) The VAB-6 regimen in the treatment of metastatic seminoma. Cancer 53: 2422

    Article  PubMed  CAS  Google Scholar 

  88. UICC (1979) TNM-Klassifikation der malignen Tumoren, 3. Aufl. Springer, Berlin Heidelberg New York, S 118

    Google Scholar 

  89. Höffken K, Schmidt CG (1977) Klassifikation und Stadieneinteilung der Hodentumoren. Deutsch Med Wochenschr 102: 249

    Article  Google Scholar 

  90. Aiginger P (1983) Einteilung der Hodentumoren. In: Aiginger P (Hrsg) Neue Aspekte in der Klinik und Fortschritte in der Chemotherapie der malignen Hodentumoren. Facultas, Wien, S 8

    Google Scholar 

Download references

Authors
  1. P. Aiginger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Kuzmits
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag/Wien

About this paper

Cite this paper

Aiginger, P., Kuzmits, R. (1989). Hodentumoren. In: Maligne Lymphome, Hodentumoren, Bronchuskarzinom, Ovarialkarzinom. Angewandte Onkologie. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3321-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-3321-7_2

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-82106-0

  • Online ISBN: 978-3-7091-3321-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation